Navigation Links
VeroScience Late-Breaking Abstract on Cycloset (A Quick Release,Formulation of Bromocriptine Mesylate) Accepted for Poster,Presentation at American Diabetes Association 67th Scientific,Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC, a privately held biotechnology and healthcare product development company, announced today that its late-breaking abstract has been accepted as a poster presentation at the 67th Scientific Sessions of the American Diabetes Association in Chicago, Ill. The abstract, entitled, "Effects of Timed Cycloset(TM) (A Quick Release Formulation of Bromocriptine Mesylate) Administration of Safety, Cardiovascular Event Rate, and Glycemic Control in Subjects with Type 2 Diabetes Receiving Diet, Oral Hypoglycemic, and/or Insulin Treatment Regimens," will be included in the category of Clinical Therapeutics/New Technology - Pharmacologic Treatment of Diabetes or its Complications and displayed Saturday, Sunday and Monday, June 23-25, in the General Poster Session in the Exhibit Hall.

VeroScience is also sponsoring a corporate symposium supported by its commercialization partner for Cycloset(TM), S2 Therapeutics, Inc., that will be held in conjunction with the American Diabetes Association's 67th Scientific Sessions. The symposium, entitled "Evolution, Hypothalamic Dopamine Neurochemistry, and Developing New Therapies for Insulin Resistance Syndrome and Type 2 Diabetes," will be held on Sunday, June 24th from 5:30-7:45 AM at the Hyatt Regency Chicago, Grand F/D South. Registration and breakfast are from 5:00-5:30 AM or you can register in advance at www.veroscience.com/ada2007registration.

Cycloset(TM), an oral, quick-release formulation of bromocriptine is a centrally-acting dopamine D2 receptor agonist that is being studied as a potential therapy in the treatment of type 2 diabetes.

VeroScience is a privately held biotechnology and healthcare product development company with main offices and laboratories in Tiverton, RI. VeroScience has a large patent portfolio tha t supports its preclinical and clinical development programs and product pipeline in the areas of metabolism, immunology, reproduction, and oncology. VeroScience leverages its intellectual property and products in out-licensing and collaborative arrangements with appropriate industry partners.

S2 Therapeutics, a privately held specialty pharmaceutical company headquartered in Bristol, TN, is the commercialization partner for Cycloset(TM) and is the holder of an exclusive global license for the manufacture, marketing and distribution of Cycloset(TM). S2 seeks opportunities in the pharmaceutical industry through in-licensing arrangements and acquisitions of novel branded prescription pharmaceutical products.


    Contacts:

    Feinstein Kean Healthcare

    Christine Cramer, 617-761-6736

    
 
christine.cramer@fkhealth.com

CONTACT: Christine Cramer of Feinstein Kean Healthcare, +1-617-761-6736,, for VeroScience, LLC christine.cramer@fkhealth.com

Web site: http://www.veroscience.com/ada2007registration/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
2. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
3. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
4. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
5. OXiGENE Abstracts Published in ASCO Program
6. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
7. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
8. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
9. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
10. Pro-Pharmaceuticals to Present Abstract at the International Society of Oncodevelopmental Biology and Medicine Conference
11. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... PureLife Dental is pleased ... separator supplier for CDA members. As part of the amalgam separator endorsement, all CDA ... saving more than $400 off the retail value. This partnership between PureLife and CDA ...
(Date:6/23/2017)... ... 2017 , ... Ulster University, Magee Campus in Northern Ireland is hosting The ... to present to graduate students exciting new and innovative hope research based on iFred’s ... The Health Improvement Service of the Western Health & Social Care Trust (WHSCT) in ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency that offers ... Texas, is announcing the launch of a new charity drive to benefit women in ... United States reveal that an estimated 252, 710 new cases of invasive or high ...
(Date:6/22/2017)... ... ... Branches, Inc. has been partnering with The Miami Foundation for over 9 ... focused on providing opportunity to low-income families and breaking the cycle of generational poverty. ... to support its , Climb to College & Career initiative which focuses on postsecondary ...
(Date:6/22/2017)... ... June 22, 2017 , ... Groove Ring is excited ... about their high performance silicon wedding bands and all-purpose rings. Whether you’re an athlete, ... silicone rings designed just for you. , From the rock face to the auto ...
Breaking Medicine News(10 mins):